000			01981 a2200553 4500
005			20250515174859.0
264		0	_c20100111
008			201001s 0 0 eng d
022			_a1573-7209
024	7		_a10.1007/s10456-009-9151-7 _2doi
040			_aNLM _beng _cNLM
100	1		_aLaMontagne, Kenneth R
245	0	0	_aA highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo. _h[electronic resource]
260			_bAngiogenesis _c2009
300			_a287-96 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdministration, Oral
650	0	4	_aAngiogenesis Inhibitors _xadministration & dosage
650	0	4	_aAnimals
650	0	4	_aCell Movement _xdrug effects
650	0	4	_aCells, Cultured
650	0	4	_aEndothelial Cells _xdrug effects
650	0	4	_aFemale
650	0	4	_aHCT116 Cells
650	0	4	_aHumans
650	0	4	_aMice
650	0	4	_aMice, Inbred C57BL
650	0	4	_aMice, Nude
650	0	4	_aMice, Transgenic
650	0	4	_aModels, Biological
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aOximes _xadministration & dosage
650	0	4	_aPhenylurea Compounds _xadministration & dosage
650	0	4	_aProtein Kinase Inhibitors _xadministration & dosage
650	0	4	_aSubstrate Specificity
650	0	4	_aVascular Endothelial Growth Factor A _xpharmacology
650	0	4	_aVascular Endothelial Growth Factor Receptor-2 _xantagonists & inhibitors
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aButler, Jeannene
700	1		_aBorowski, Virna B
700	1		_aFuentes-Pesquera, Angel R
700	1		_aBlevitt, Jonathan M
700	1		_aHuang, Shenlin
700	1		_aLi, Ronghua
700	1		_aConnolly, Peter J
700	1		_aGreenberger, Lee M
773	0		_tAngiogenesis _gvol. 12 _gno. 3 _gp. 287-96
856	4	0	_uhttps://doi.org/10.1007/s10456-009-9151-7 _zAvailable from publisher's website
999			_c18962065 _d18962065